Skip to content
AnalystLens

Corteva, Inc. 8-K Report, Financial Results (May 1, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 1, 2024
Period End
May 1, 2024
Security
CTVA
In the record · 2019–202610-K710-Q238-K85

CTVA filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 85 current reports (8-K) between 2019 and 2026.

  1. Change in control8-K · Jun ’19Jun ’19
  2. Leadership change8-K · Feb ’21Feb ’21
  3. Restructuring8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.

Corteva (CTVA) reported first-quarter 2024 results that were largely in line with management's expectations, with GAAP net sales of $4.49 billiona (down 8% year over year, or 6% on an organic basis) and GAAP EPS from continuing operations of $0.53 (down 37%).

Non-GAAP Operating EBITDA was $1.03 billionb (down 16%) and Operating EPS was $0.89 (down 23%). The results were split sharply by segment: Seed performed well, with net sales up 2% and segment operating EBITDA up 15% on price gains of 6% and a roughly 300 basis point margin improvement, while Crop Protection was weak, with net sales down 20%, operating EBITDA down 49%, and segment margin down more than 970 basis points, driven by a 18% volume decline as farmers bought closer to application windows and destocking persisted in EMEA. Management reaffirmed full-year 2024 guidance: net sales of $17.4 to $17.7 billion, Operating EBITDA of $3.5 to $3.7 billion, Operating EPS of $2.70 to $2.90, and Free Cash Flow of $1.5 to $2.0 billion, with about $1.0 billion of planned share repurchases.

Management expects Crop Protection growth to return in the second half of 2024, supported by its portfolio, biologicals, and cost actions. Investors should note that the quarter's GAAP results were weighed down by $127 millionc of pre-tax significant items, including an estimated $54 million Lorsban-related settlement charge and $75 million of restructuring and asset-related charges, and that the company expects $180 to $230 million of 2024 restructuring charges tied to its Crop Protection network optimization.

The key question for investors is whether the second-half Crop Protection recovery materializes, since the guidance depends on it. Balance sheet items also merit attention: short-term borrowings rose to $2.1 billiond from $198 million at year-end 2023, and cash fell to $1.5 billion, reflecting the seasonal working capital build typical of the first quarter, with operating cash flow from continuing operations of negative $2.6 billion.

02—Key points

Key Highlights

  1. GAAP net sales were $4.49 billion, down 8% year over year (organic down 6%); Seed net sales rose 2% to $2.75 billion while Crop Protection fell 20% to $1.74 billion.
  2. Seed segment operating EBITDA rose 15% to $748 million, with price up 6% globally and margin improving about 300 basis points.
  3. Crop Protection operating EBITDA fell 49% to $310 million, with volume down 18% and segment margin down more than 970 basis points, reflecting weak demand, price pressure, and raw material inflation.
  4. GAAP EPS from continuing operations was $0.53 (down 37%); non-GAAP Operating EPS was $0.89 (down 23%), with $127 million of pre-tax significant items weighing on GAAP results.
  5. Full-year 2024 guidance was reaffirmed: net sales of $17.4-$17.7 billion, Operating EBITDA of $3.5-$3.7 billion, Operating EPS of $2.70-$2.90, and Free Cash Flow of $1.5-$2.0 billion.
  6. The company plans about $1.0 billion in share repurchases in 2024 and expects $180-$230 million of net pre-tax restructuring charges tied to its Crop Protection network optimization.
  7. Short-term borrowings increased to $2.1 billion from $198 million at year-end 2023, and cash and equivalents declined to $1.5 billion, while accounts receivable rose to $7.9 billion on seasonal working capital needs.

03—Questions

Frequently Asked Questions

  1. Did Corteva change its full-year 2024 outlook?

    No. Corteva reaffirmed its 2024 guidance, including net sales of $17.4-$17.7 billion, Operating EBITDA of $3.5-$3.7 billion, and Operating EPS of $2.70-$2.90. Management said first-quarter results were largely as expected and expects Crop Protection growth in the second half of 2024.

  2. Why did Crop Protection results decline so sharply?

    Crop Protection net sales fell 20%, driven mainly by an 18% volume decline. Management attributed this to a strong prior-year comparison, farmers shifting to just-in-time purchasing closer to the application window, weather and destocking impacts in EMEA, and competitive pricing pressure in North America and Latin America.

  3. What drove the strength in the Seed business?

    Seed net sales rose 2% (5% organically), led by a 6% price increase from the company's price-for-value strategy and favorable product mix. Volume gains in North America from higher corn deliveries were partly offset by delayed demand in EMEA due to unfavorable weather. Segment operating EBITDA grew 15%.

  4. Why were GAAP earnings much lower than non-GAAP earnings?

    GAAP EPS of $0.53 is reduced by items excluded from Operating EPS of $0.89, including $0.13 per share of significant items (such as restructuring charges and an estimated Lorsban-related settlement expense), $0.17 per share of amortization of intangibles from the separation, and $0.06 per share of non-operating costs.

  5. What should investors watch for going forward?

    Investors should watch whether Crop Protection demand and pricing recover in the second half of 2024, as guidance relies on that improvement. They should also monitor the $180-$230 million of restructuring charges expected in 2024, the rise in short-term borrowings, and whether the planned $1.0 billion of share repurchases and the Free Cash Flow target of $1.5-$2.0 billion are achieved.

04—Continue

← View all 8-K filings